AMA submission on Government proposals to increase biosimilar prescribing
The AMA encourages medical practitioners to offer generic medicine choices when it is safe and appropriate to do so. However prescribing regulations, such as the PBS Authority policy, should not pose a barrier to medical practitioners treating their patients or impose an administrative burden without evidence that they are effective and necessary. A blunt regulatory tool like the PBS Authority system is not the way to increase prescribing of biosimilars.
Published: 19 Oct 2017